{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:05:55Z","timestamp":1777590355725,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.rdc.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T14:50:00Z","timestamp":1686927000000},"page":"563-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Jessica L.","family":"Bloom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.rdc.2023.03.006_bib1","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.1780330804","article-title":"Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis","volume":"33","author":"Lie","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.006_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","article-title":"Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"17","author":"Jennette","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.006_bib3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sabl\u00e9-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib5","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.006_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3899\/jrheum.120808","article-title":"Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort","volume":"40","author":"Gendelman","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.semarthrit.2008.05.004","article-title":"Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients","volume":"39","author":"Zwerina","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.03.006_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","article-title":"Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome)","volume":"48-49","author":"Mouthon","year":"2014","journal-title":"J Autoimmunr"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.006_bib10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","article-title":"The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis","volume":"12","author":"G\u00f3mez-Puerta","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/BOR.0b013e3280119854","article-title":"Churg-Strauss syndrome","volume":"19","author":"Pagnoux","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50441-4","article-title":"Effects of Model, Method of Collection, and Topography on Chemical Elements and Metals in the Aerosol of Tank-Style Electronic Cigarettes","volume":"9","author":"Williams","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","article-title":"Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study","volume":"53","author":"Detoraki","year":"2016","journal-title":"J\u00a0Asthma"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib14","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1067\/mai.2001.117176","article-title":"The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report","volume":"108","author":"Weller","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40413-018-0217-0","article-title":"Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases","volume":"11","author":"Celebi Sozener","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib17","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.22834","article-title":"HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome","volume":"56","author":"Vaglio","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.23209","article-title":"Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et\u00a0al","volume":"58","author":"Wieczorek","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.006_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/art.23496","article-title":"Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis","volume":"58","author":"Wieczorek","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.03.006_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: an overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2023.03.006_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000210656","article-title":"Cytokine production profile of CD4+ T\u00a0cells from patients with active Churg-Strauss syndrome tends toward Th17","volume":"149","author":"Saito","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2023.03.006_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000327265","article-title":"The proportion of regulatory T\u00a0cells in the peripheral blood reflects the relapse or remission status of patients with Churg-Strauss syndrome","volume":"155","author":"Saito","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.006_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","article-title":"Decreases in the numbers of peripheral blood regulatory T\u00a0cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis","volume":"33","author":"Tsurikisawa","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.rdc.2023.03.006_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1361.053","article-title":"Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome","volume":"1051","author":"Hellmich","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of Eosinophilic End-Organ Manifestations","volume":"35","author":"Akuthota","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4 Pt 2","key":"10.1016\/j.rdc.2023.03.006_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.lpm.2013.01.005","article-title":"L4. Eosinophils: how they contribute to endothelial damage and dysfunction","volume":"42","author":"Roufosse","year":"2013","journal-title":"Presse Med"},{"issue":"6442","key":"10.1016\/j.rdc.2023.03.006_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/bmj.289.6442.400","article-title":"Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome","volume":"289","author":"Tai","year":"1984","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2012.07.027","article-title":"Novel targeted therapies for eosinophilic disorders","volume":"130","author":"Wechsler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2011.155382","article-title":"IgG4 immune response in Churg-Strauss syndrome","volume":"71","author":"Vaglio","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.rdc.2023.03.006_bib31","article-title":"Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders","author":"Makiya","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","article-title":"Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome","volume":"63","author":"Lanham","year":"1984","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.rdc.2010.05.003","article-title":"Clinical manifestations and treatment of Churg-Strauss syndrome","volume":"36","author":"Baldini","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.006_bib34","first-page":"477","article-title":"Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases","volume":"52","author":"Chumbley","year":"1977","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib36","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/art.21253","article-title":"Churg-Strauss syndrome: just one disease entity?","volume":"52","author":"Kallenberg","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.006_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr2.11263","article-title":"Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America","volume":"3","author":"Doubelt","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.berh.2009.02.004","article-title":"Churg-Strauss angiitis","volume":"23","author":"Sinico","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.006_bib39","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10067-010-1530-3","article-title":"Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis","volume":"29","author":"Szczeklik","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/art.27263","article-title":"Cardiac involvement in Churg-Strauss syndrome","volume":"62","author":"Dennert","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2015.04.013","article-title":"Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients","volume":"14","author":"Dunogu\u00e9","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib42","first-page":"51","article-title":"The significance of cardiac magnetic resonance imaging in detection and monitoring of the treatment efficacy of heart involvement in eosinophilic granulomatosis with polyangiitis patients","volume":"33","author":"Fijolek","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.006_bib43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/rheumatology\/kes155","article-title":"Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients","volume":"52","author":"Marmursztejn","year":"2013","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.006_bib44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.revmed.2010.04.009","article-title":"[Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review]","volume":"31","author":"Sauvetre","year":"2010","journal-title":"Rev Med Interne. Sep"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.006_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2007.07.005","article-title":"Pulmonary eosinophilic syndromes","volume":"27","author":"Wechsler","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.006_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0038-1669454","article-title":"Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)","volume":"39","author":"Nguyen","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib49","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"20","key":"10.1016\/j.rdc.2023.03.006_bib50","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJM196611172752003","article-title":"Fatal strongyloidiasis in patients receiving corticosteroids","volume":"275","author":"Cruz","year":"1966","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.006_bib51","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib54","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.006_bib57","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","article-title":"Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies","volume":"60","author":"Menditto","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib58","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.006_bib59","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s10067-019-04891-w","article-title":"Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab","volume":"39","author":"Casal Moura","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"19","key":"10.1016\/j.rdc.2023.03.006_bib60","first-page":"10","article-title":"B-Cell-Depleting Therapy Improves Myocarditis in Seronegative Eosinophilic Granulomatosis with Polyangiitis","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.006_bib62","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib63","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1 Suppl 57","key":"10.1016\/j.rdc.2023.03.006_bib64","first-page":"24","article-title":"Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study","volume":"28","author":"Metzler","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"3 Suppl 49","key":"10.1016\/j.rdc.2023.03.006_bib65","first-page":"S35","article-title":"A\u00a0phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome","volume":"26","author":"Metzler","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.006_bib67","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.rdc.2023.03.006_bib68","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6 Suppl 36","key":"10.1016\/j.rdc.2023.03.006_bib69","first-page":"S52","article-title":"Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"issue":"26","key":"10.1016\/j.rdc.2023.03.006_bib70","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.006_bib71","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2133.2003.05807.x","article-title":"Churg-Strauss syndrome: successful treatment with mycophenolate mofetil","volume":"150","author":"Assaf","year":"2004","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.006_bib72","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00296-021-04961-w","article-title":"A\u00a0real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis","volume":"41","author":"Philobos","year":"2021","journal-title":"Rheumatol Int"},{"issue":"21","key":"10.1016\/j.rdc.2023.03.006_bib73","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2023.03.006_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.rdc.2023.03.006_bib75","unstructured":"FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome. 2017. Avilable at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-eosinophilic-granulomatosis-polyangiitis-rare-disease-formerly-known-churg."},{"issue":"20","key":"10.1016\/j.rdc.2023.03.006_bib76","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.006_bib77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 4","key":"10.1016\/j.rdc.2023.03.006_bib78","first-page":"A1","article-title":"Glucocorticoid sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"73","author":"Kent","year":"2018","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.006_bib79","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rdc.2023.03.006_bib80","unstructured":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA). ClinicalTrials.gov Identifier: NCT04157348. Updated September 2, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04157348. Accessed September 25, 2022."},{"key":"10.1016\/j.rdc.2023.03.006_bib81","unstructured":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN). ClinicalTrials.gov Identifier: NCT05263934. Updated September 16, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05263934. Accessed September 25, 2022."},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"19","key":"10.1016\/j.rdc.2023.03.006_bib83","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.006_bib84","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.rdc.2023.03.006_bib85","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.006_bib86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2023.03.006_bib87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"17","key":"10.1016\/j.rdc.2023.03.006_bib88","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.006_bib89","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002160","article-title":"Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry","volume":"8","author":"Pu\u00e9chal","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2023.03.006_bib91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fped.2018.00226","article-title":"Primary Vasculitis in Childhood: GPA and MPA in Childhood","volume":"6","author":"Jariwala","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.rdc.2023.03.006_bib92","series-title":"Textbook of Pediatric Rheumatology","author":"Petty","year":"2021"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.006_bib93","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/ppul.24089","article-title":"Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRare\u00ae cohort","volume":"53","author":"Fina","year":"2018","journal-title":"Pediatr Pulmonol. Dec"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.006_bib94","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/rheumatology\/kew029","article-title":"Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK","volume":"55","author":"Eleftheriou","year":"2016","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.006_bib95","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.39122","article-title":"Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry","volume":"67","author":"Iudici","year":"2015","journal-title":"Arthritis Rheumatol. Jul"},{"key":"10.1016\/j.rdc.2023.03.006_bib96","unstructured":"FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels. 2019. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-children-rare-diseases-cause-inflammation-small-blood-vessels."},{"issue":"6","key":"10.1016\/j.rdc.2023.03.006_bib97","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/ppul.25286","article-title":"Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children","volume":"56","author":"Hinds","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"24","key":"10.1016\/j.rdc.2023.03.006_bib98","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.2169\/internalmedicine.3406-19","article-title":"A\u00a0Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab","volume":"58","author":"Nara","year":"2019","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.006_bib99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.006_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00016480500437435","article-title":"Ear, nose and throat manifestations of Churg-Strauss syndrome","volume":"126","author":"Bacciu","year":"2006","journal-title":"Acta Otolaryngol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:30:32Z","timestamp":1760182232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889857X23000376"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}